Results 271 to 280 of about 1,700,721 (365)

Mobilizing mine lands for biobased decarbonization strategies

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract Over 163 000 ha of mine lands in Pennsylvania (PA) have the potential to produce willow as a feedstock for renewable energy generation. Each year these lands could produce between 454 000 and 907 000 dry Mg of willow, which can be a feedstock for bioenergy (i.e., biopower) with carbon capture and sequestration (BECCS) or sustainable aviation ...
Mallory Wahlstrom   +4 more
wiley   +1 more source

Health insurance and kidney transplantation outcomes in the United States: a systematic review and AI-driven analysis of disparities in access and survival. [PDF]

open access: yesRen Fail
Garcia Valencia OA   +13 more
europepmc   +1 more source

Delivered cost of switchgrass pellets transported from depots to a biorefinery in the Piedmont, USA

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract The southeast region of the USA has the potential to be a significant producer of biobased products; however, research is needed to demonstrate the most cost‐effective feedstock delivery system. This study considers a distributed network of five pellet depots to supply feedstock (i.e., switchgrass pellets) for the operation of a hypothetical ...
Jonathan P. Resop   +2 more
wiley   +1 more source

Attendance patterns in well-child visits across diverse pediatric populations, Midwestern United States. [PDF]

open access: yesPrev Med Rep
Luff A   +8 more
europepmc   +1 more source

Production of a nutrient enriched biochar: a techno‐economic feasibility analysis

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract A techno‐economic feasibility analysis was conducted for a biomass pyrolysis plant that utilized Eucalyptus to produce fertilizer‐enriched biochar. Key parameters – biomass throughput, fertilizer loading, and selling price – were optimized for financial viability using net present value (NPV), internal rate of return (IRR), return on ...
Brendon Trollip, Ryan David Merckel
wiley   +1 more source

A single‐centre analysis of a biosimilar switching programme for adalimumab in inflammatory bowel disease

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Amgevita is a licensed biosimilar to adalimumab, having demonstrated high pharmacokinetic and clinical similarity to Humira. Switching to a lower‐cost medicine may elicit a nocebo effect, whereby expectations of poorer efficacy impact outcomes despite pharmacological similarity. This prospective cohort study examined clinical and economic outcomes
Louise Rabbitt   +7 more
wiley   +1 more source

Switching disease‐modifying therapies in patients with spinal muscular atrophy: A systematic review on effectiveness outcomes

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
With multiple disease‐modifying therapies now available, treatment switching has become an important clinical consideration in the management of spinal muscular atrophy (SMA). While some switches are prompted by suboptimal clinical response, more commonly they are driven by treatment burden, convenience, or adverse events.
Andrej Belančić   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy